@Parsifaler Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? https://t.co/N3hwc6awTM
RT @aime3verde: 14/ Mechanism 15: Action on high mobility group box 1 (HMGB1) Ivermectin induces autophagy and release of ATP and HMGB1.…
RT @aime3verde: 14/ Mechanism 15: Action on high mobility group box 1 (HMGB1) Ivermectin induces autophagy and release of ATP and HMGB1.…
RT @aime3verde: 14/ Mechanism 15: Action on high mobility group box 1 (HMGB1) Ivermectin induces autophagy and release of ATP and HMGB1.…
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? https://t.co/RmhyvSry3F damage, debris Part 1 https://t.co/aUF15L9twc
Another article about COVID-19 and gender-related death rates associated with HMGB1. https://t.co/3wnDZFiF5B
RT @MolMedBMC: Check out one of our recent publications on Covid-19, "Extracellular HMGB1: a therapeutic target in severe pulmonary inflamm…
Check out one of our recent publications on Covid-19, "Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?" https://t.co/8gP7Xa1MT4 https://t.co/ZL5MByRPEv
RT @OttestadWilliam: The nuclear weapon in the immune arsenal and the possible link to COVID-19 https://t.co/MB4CKcMYpX
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? https://t.co/6CqyplC2KG
RT @HMGBiotech: Extracellular #HMGB1: a therapeutic target in severe pulmonary #inflammation including #COVID-19?. The endogenous damage-as…
RT @HMGBiotech: Extracellular #HMGB1: a therapeutic target in severe pulmonary #inflammation including #COVID-19?. The endogenous damage-as…
RT @HMGBiotech: Extracellular #HMGB1: a therapeutic target in severe pulmonary #inflammation including #COVID-19?. The endogenous damage-as…
Extracellular #HMGB1: a therapeutic target in severe pulmonary #inflammation including #COVID-19?. The endogenous damage-associated molecular pattern (DAMP) molecule HMGB1 initiates inflammation via two separate pathways... https://t.co/b3FGt76VZ8 https://
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? | Molecular Medicine | Full Text https://t.co/j970JskvKw
A great, easy to read article. Many potential anti #HMGB1 agents mentioned amongst them licorice & ketamine
@PulmCrit There is one more rationale for ketamine and dexmedetomidine They attenuate HMGB1 through different mechanisms. Would love to hear your thoughts on this paper by Andersson, @OttestadWilliam and @KevinJTraceyMD Read from bottom up if you are in
RT @ScienceSaiyan: Massive release of the protein #HMGB1 in the #lungs may contribute to the lung damage seen in severe #COVID19 cases @ka…
RT @SonoRambler: @OttestadWilliam @emcrit @PulmCrit @cliffreid Now is a good time to read up on HMGB1; "The nuclear weapon of the immune…
RT @Inflamma_some: Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? https://t.co/eoFiv6bFN3
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? https://t.co/eoFiv6bFN3
Massive release of the protein #HMGB1 in the #lungs may contribute to the lung damage seen in severe #COVID19 cases @karolinskainst @BioMedCentral #pneumonia #coronavirus https://t.co/04WQG1lAW9
RT @OttestadWilliam: The nuclear weapon in the immune arsenal and the possible link to COVID-19 https://t.co/MB4CKcMYpX
@OttestadWilliam @emcrit @PulmCrit @cliffreid Now is a good time to read up on HMGB1; "The nuclear weapon of the immune arsenal" (Lotze '05) Common drugs you use in COVID-19 patients interact with this upstream pro-inflammatory molecule, explore how. h
The nuclear weapon in the immune arsenal and the possible link to COVID-19 https://t.co/MB4CKcMYpX